Editas Medicine, Inc. (EDIT)
- Previous Close
5.56 - Open
5.52 - Bid 5.36 x 100
- Ask 5.41 x 100
- Day's Range
5.36 - 5.69 - 52 Week Range
4.91 - 11.91 - Volume
541,974 - Avg. Volume
2,012,611 - Market Cap (intraday)
444.496M - Beta (5Y Monthly) 2.08
- PE Ratio (TTM)
-- - EPS (TTM)
-2.07 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.36
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
www.editasmedicine.comRecent News: EDIT
Performance Overview: EDIT
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EDIT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EDIT
Valuation Measures
Market Cap
457.24M
Enterprise Value
195.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.35
Price/Book (mrq)
1.55
Enterprise Value/Revenue
2.81
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-239.36%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
69.41M
Net Income Avi to Common (ttm)
-166.13M
Diluted EPS (ttm)
-2.07
Balance Sheet and Cash Flow
Total Cash (mrq)
323.11M
Total Debt/Equity (mrq)
10.47%
Levered Free Cash Flow (ttm)
--
Research Analysis: EDIT
Company Insights: EDIT
EDIT does not have Company Insights